Anaplastic lymphoma kinase (ALK) Inhibitor

Anaplastic lymphoma kinase (ALK) Inhibitors (129):

Cat. No.	Product Name	Effect	Purity

HY-147219A

SIAIS164018 hydrochloride	Inhibitor	99.84%
SIAIS164018 hydrochloride is a PROTAC-based ALK and EGFR degrader, with IC₅₀ value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 hydrochloride strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 hydrochloride exhibits better property than Brigatinib (HY-12857).

HY-50878S

Crizotinib-d₅	Inhibitor	99.60%
Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.

HY-13326

ASP3026	Inhibitor	99.88%
ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC₅₀ value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research.

HY-10432G

A 83-01 (GMP)	Inhibitor
A 83-01 (GMP) is A 83-01 (HY-10432) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. A 83-01 is a potent ALK4/5/7 inhibitor.

HY-156467A

Neladalkib TFA	Inhibitor
Neladalkib TFA is the TFA salt form of Neladalkib (HY-156467). Neladalkib (NVL-655) is an oral ALK inhibitor, the IC₅₀ for Neladalkib in inhibiting ALK is 2.8 nM. Neladalkib promotes cell apoptosis and has anti-tumor activity.

HY-15801

HG-14-10-04	Inhibitor	99.09%
HG-14-10-04 is a potent ALK and mutant EGFR inhibitor with IC₅₀s of 20 nM, 15.6 nM, 22.6 nM and 124.5 nM for ALK, EGFR^LR/TM, EGFR^19del/TM/CS and EGFR^LR/TM/CS, respectively. HG-14-10-04 can be used to research anticancer.

HY-160520

ALK-IN-28	Inhibitor	99.30%
ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK).

HY-122582

TL13-12	Inhibitor	98.06%
TL13-12 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC₅₀ value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, FER, PTK2, and RPS6KA1 with IC₅₀ values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the Cereblon ligand of Pomalidomide (HY-10984).

HY-15358

ALK inhibitor 2	Inhibitor	99.57%
ALK inhibitor 2 (compound 18) is a potent pyrimidin ALK inhibitor. ALK inhibitor 2 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC₅₀=37 nM) and focal adhesion kinase (FAK; IC₅₀=5 nM).

HY-112156

MS4077	Inhibitor	99.66%
MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a K_d of 37 nM for binding affinity to ALK.

HY-N4126

6-Demethoxytangeretin	Inhibitor	99.37%
6-Demethoxytangeretin is a flavonoid compound that can be isolated from Citrus reticulata. 6-Demethoxytangeretin has anti-inflammatory and anti-allergic activities and can inhibit the production of IL-6 and the expression of related genes in human mast cells through the ALK and MAPK pathways. 6-Demethoxytangeretin can promote CRE-mediated transcription in hippocampal neurons.

HY-15357

ALK inhibitor 1	Inhibitor	99.62%
ALK inhibitor 1 (compound 17) is a potent pyrimidin ALK inhibitor. ALK inhibitor 1 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC₅₀=31 nM) and focal adhesion kinase (FAK; IC₅₀=2 nM).

HY-148933

ALKBH5-IN-2	Inhibitor
ALKBH5-IN-2 (compound 6) is a potent ALKBH5 inhibitor with an IC₅₀ value of 0.79 µM. ALKBH5-IN-2 inhibits cell viability.

HY-112801

F-1	Inhibitor	98.03%
F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC₅₀s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK^WT, ROS1^WT, ALK^L1196M and ALK^G1202R, respectively.

HY-111752

EML4-ALK kinase inhibitor 1	Inhibitor	98.02%
EML4-ALK kinase inhibitor 1 is a potent orally active inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), with an IC₅₀ of 1 nM.

HY-112140

JH-VIII-157-02	Inhibitor	99.67%
JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC₅₀ of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells.

HY-147219

SIAIS164018	Inhibitor
SIAIS164018 is a PROTAC-based ALK and EGFR degrader, with IC₅₀ value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 exhibits better property than Brigatinib (HY-12857).

HY-15656S

Ceritinib-d₇	Inhibitor	98.00%
Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

HY-135887

ZX-29	Inhibitor	99.52%
ZX-29 is a potent and selective ALK inhibitor with an IC₅₀ of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR. ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect.

HY-136194

TL13-22	Inhibitor	99.71%
TL13-22 is a negative control for TL13-12 (HY-122582) and a potent ALK inhibitor with an IC₅₀ of 0.54 nM. TL13-22 does not degrade ALK in cells.

Name
Email *

	Sorry, but the email address you supplied was invalid.